Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

87.67 +0.36 (+0.41%)
Streaming Delayed Price Updated: 10:08 AM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
From Incyte
Via Business Wire
Incyte to Report Third Quarter Financial Results
From Incyte
Via Business Wire
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
From Incyte
Via Business Wire
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
From Incyte
Via Business Wire
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
From Incyte
Via Business Wire
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
From Incyte
Via Business Wire
Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
From Incyte
Via Business Wire
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis
From Incyte
Via Business Wire
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025
From Incyte
Via Business Wire
Incyte to Report Second Quarter Financial Results
From Incyte
Via Business Wire
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte Corporation
Via Business Wire
Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
From Incyte
Via Business Wire
Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis
From Incyte
Via Business Wire
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
From QIAGEN N.V.
Via Business Wire
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
From Incyte
Via Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
From Incyte
Via Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
From Incyte
Via Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025
From Incyte
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.